{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:22:12Z","timestamp":1794867732748,"version":"4.9.1"},"reference-count":56,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Science Progress"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate glucagon-like peptide-1 receptor agonist (GLP-1 RA)-specific associations with hair loss, characterize reported alopecia subtypes and discuss potential underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search was conducted across four databases (PubMed, Embase, Scopus, and Web of Science) according to PRISMA guidelines and registered in PROSPERO (CRD420261297384). Studies were included if they were primary articles assessing hair loss related to GLP-1 RA use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 133 studies identified, 24 met inclusion criteria. Among GLP-1 RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies. Although infrequently classified overall, androgenetic alopecia and telogen effluvium were the predominant subtypes of hair loss reported. Tirzepatide, associated with the greatest magnitude of weight loss, was most frequently linked to telogen effluvium. Hair loss associated with semaglutide appeared to be dose-dependent, with doses &lt; 2mg weekly rarely implicated while higher obesity-treatment doses were more commonly associated with hair loss. Females appeared to be disproportionately affected. Rapid weight loss emerged as a potential contributor, particularly for telogen effluvium. In contrast, fewer studies assessed hair loss with liraglutide, dulaglutide, lixisenatide and exenatide, and they typically exhibited lower reported risk when compared to semaglutide and tirzepatide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Accumulating evidence from pharmacovigilance databases and clinical cohorts suggests an increased risk of hair loss with certain GLP-1 RAs, particularly semaglutide and tirzepatide. Further studies are needed to clarify the etiology of drug-induced weight loss, identify vulnerable populations, and establish causality and temporal relationship through large, prospective randomized trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00368504261444578","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:48:31Z","timestamp":1776484111000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling"],"prefix":"10.1177","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"University of Toronto"},{"name":"Mediprobe Research Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8228-2449","authenticated-orcid":false,"given":"Elizabeth M.","family":"Teasell","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-7254","authenticated-orcid":false,"given":"Vasiliki","family":"Economopoulos","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-2995","authenticated-orcid":false,"given":"Paradi","family":"Mirmirani","sequence":"additional","affiliation":[{"name":"The Permanente Medical Group"},{"name":"University of California"},{"name":"Case Western Reserve University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20197"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01185-6"},{"key":"e_1_3_4_5_2","first-page":"1","article-title":"Associations Between GLP-1 Receptor Agonists and Alopecia: A Multi-Centre Retrospective Analysis and Public Interest Trends","author":"Ching LM","year":"2025","unstructured":"Ching LM, Guirguis CA, Tung JK. Associations Between GLP-1 Receptor Agonists and Alopecia: A Multi-Centre Retrospective Analysis and Public Interest Trends. JEADV Clinical Practice 2025; 1\u20135. https:\/\/doi.org\/10.1002\/jvc2.70208","journal-title":"JEADV Clinical Practice"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17971"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.08.033"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.01.046"},{"key":"e_1_3_4_9_2","first-page":"e8320","article-title":"Telogen Effluvium: A Review of the Literature","volume":"12","author":"Asghar F","year":"2020","unstructured":"Asghar F, Shamim N, Farooque U, et al. Telogen Effluvium: A Review of the Literature. Cureus 2020; 12: e8320. https:\/\/doi.org\/10.7759\/cureus.8320","journal-title":"Cureus"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02597-w"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-025-00730-0"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00150-5"},{"key":"e_1_3_4_14_2","first-page":"1","article-title":"Risk of Hair Loss with Semaglutide for Weight Loss","author":"Sodhi M","year":"2026","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, et al. Risk of Hair Loss with Semaglutide for Weight Loss. medRxiv 2026; 1\u201310.","journal-title":"medRxiv"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.06.228"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2025.100674"},{"key":"e_1_3_4_17_2","first-page":"e181","article-title":"Cross-Sectional analysis of adverse dermatologic events reported to the FDA after use of GLP-1 agonists","volume":"23","author":"Ituarte BE","year":"2024","unstructured":"Ituarte BE, Taylor MA, Thomas SI, et al. Cross-Sectional analysis of adverse dermatologic events reported to the FDA after use of GLP-1 agonists. Journal of Drugs in Dermatology 2024; 23: e181\u2013e182.","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.8605"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-024-07613-w"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.9448"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16376"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.822"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001037756.86286.5e"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae547"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2016.10.076"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjnph-2023-000733"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdrv.2025.04.009"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20512"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1228"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.03.021"},{"key":"e_1_3_4_31_2","volume-title":"Wegovy \u00ae (semaglutide injection) Product Monograph","year":"2025","unstructured":"Wegovy \u00ae (semaglutide injection) Product Monograph. https:\/\/www.novonordisk.ca\/content\/dam\/nncorp\/ca\/en\/products\/Wegovy-product-monograph.pdf (2025, accessed 22 January 2026)."},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-025-07903-8"},{"key":"e_1_3_4_34_2","volume-title":"Zepbound: Highlights of prescribing information","year":"2026","unstructured":"Zepbound: Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/217806s037lbl.pdf (2026, accessed 22 January 2026)."},{"key":"e_1_3_4_35_2","volume-title":"Victoza (liraglutide): Highlights of prescribing information","year":"2025","unstructured":"Victoza (liraglutide): Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/022341s046lbl.pdf (2025, accessed 22 January 2026)."},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/cob.70070"},{"key":"e_1_3_4_37_2","first-page":"e14617","article-title":"Bariatric Surgery-Induced Telogen Effluvium (Bar SITE): Case Report and a Review of Hair Loss Following Weight Loss Surgery","volume":"13","author":"Cohen-Kurzrock RA","year":"2021","unstructured":"Cohen-Kurzrock RA, Cohen PR. Bariatric Surgery-Induced Telogen Effluvium (Bar SITE): Case Report and a Review of Hair Loss Following Weight Loss Surgery. Cureus 2021; 13: e14617. https:\/\/doi.org\/10.7759\/cureus.14617","journal-title":"Cureus"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.5021\/ad.24.043"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2025.108378"},{"key":"e_1_3_4_40_2","unstructured":"Telogen Effluvium and Alopecia Rates High in GLP-1 RA Users. Medscape. https:\/\/www.medscape.com\/viewarticle\/telogen-effluvium-and-androgenic-alopecia-rates-high-among-2025a1000oo9 (2025 accessed 27 January 2026)."},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1159\/000544023"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-025-02005-0"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108834"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijt.ijt_57_24"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70063"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2006-0020"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.5070\/D3225030937"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom13071068"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2006.02.007"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.846903"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2018.06.028"},{"key":"e_1_3_4_52_2","first-page":"42","article-title":"A review of Glucagon-like Peptide-1 in Dermatology","volume":"18","author":"Patino W","year":"2025","unstructured":"Patino W, Thomas A, Jain S, et al. A review of Glucagon-like Peptide-1 in Dermatology. Journal of Clinical and Aesthetic Dermatology 2025; 18: 42\u201350.","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S173082"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-022-07803-2"},{"key":"e_1_3_4_55_2","first-page":"1030","article-title":"Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review","volume":"5","author":"Branyiczky MK","year":"2025","unstructured":"Branyiczky MK, Lowe MS, McMullen E, et al. Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review. Int J Dermatol 2025; 5: 1030\u201331032. https:\/\/doi.org\/10.1111\/ijd.70133","journal-title":"Int J Dermatol"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.04.058"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.06.001"}],"container-title":["Science Progress"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00368504261444578","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00368504261444578","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00368504261444578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:45:55Z","timestamp":1782848755000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00368504261444578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/00368504261444578"],"URL":"https:\/\/doi.org\/10.1177\/00368504261444578","relation":{},"ISSN":["0036-8504","2047-7163"],"issn-type":[{"value":"0036-8504","type":"print"},{"value":"2047-7163","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"00368504261444578"}}